Literature DB >> 23994185

ALX 1393 inhibits spontaneous network activity by inducing glycinergic tonic currents in the spinal ventral horn.

V-S Eckle1, B Antkowiak.   

Abstract

BACKGROUND: Strychnine-sensitive glycine receptors are activated by glycine and facilitate chloride influx into neurons. Glycinergic transmission might be either mediated by synaptic or extrasynaptic glycine receptors. While phasic neurotransmission is provided by a synaptic pathway, activation of extrasynaptic glycine receptors induces tonic inhibition. The glycine transporter 2 (GlyT2) regulates the uptake of glycine into presynaptic boutons. It is not determined yet, whether inhibition of GlyT2 by ALX 1393 can produce inhibition of spinal motoric networks and, whether phasic or tonic glycinergic inhibition is mostly enhanced.
METHODS: We investigated the effect of ALX 1393 on spontaneous action potential firing activity by extracellular recordings in the ventral horn area of organotypic spinal cultures. Additionally, using the whole-cell patch-clamp technique, we defined the influence of GlyT2 inhibition on tonic and phasic glycinergic transmission in commissural interneurons of the ventral horn.
RESULTS: GlyT2 inhibition by ALX 1393 potently reduced neuronal action potential activity in a concentration-dependent manner (n=211). The half maximal effect of ALX 1393 was observed at 100 ± 31 nM. Moreover, 88.3 ± 2.6% of the action potential activity was suppressed at 1 μM. Whole-cell patch-clamp recordings unveiled that ALX 1393 (200 nM) induced a tonic current (-45.7 ± 11.6 pA, n=5) that was significantly reversed by application of the competitive glycine receptor antagonist strychnine. Contrastingly, phasic glycinergic transmission was not augmented by GlyT2 inhibition (charge transferred per time period for control conditions: 1.1 ± 0.1 pC, n=7, for ALX 1393: 0.9 ± 0.2 pC, n=7, p>0.05).
CONCLUSION: GlyT2 inhibition induced glycinergic tonic currents, which might be the underlying mechanism for the observed suppression of spontaneous action potential activity by ALX 1393 in the spinal ventral horn. Silencing neuronal action potential activity by blocking GlyT2 might be a novel principle to inhibit locomotor circuits in the ventral horn area and to induce muscle relaxation.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACSF; ALX 1393; GlyT2; IPSCs; artificial cerebrospinal fluid; glycine receptor; glycine transporter 2; glycine transporter type 2; inhibitory postsynaptic currents; organotypic culture; spinal cord; ventral horn

Mesh:

Substances:

Year:  2013        PMID: 23994185     DOI: 10.1016/j.neuroscience.2013.08.042

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

Review 1.  Glycine receptors and glycine transporters: targets for novel analgesics?

Authors:  Hanns Ulrich Zeilhofer; Mario A Acuña; Jacinthe Gingras; Gonzalo E Yévenes
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

2.  4-bromopropofol decreases action potential generation in spinal neurons by inducing a glycine receptor-mediated tonic conductance.

Authors:  V S Eckle; C Grasshoff; V Mirakaj; P M O'Neill; N G Berry; M Leuwer; B Antkowiak
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 3.  Glycinergic transmission: glycine transporter GlyT2 in neuronal pathologies.

Authors:  Francisco Zafra; Ignacio Ibáñez; Cecilio Giménez
Journal:  Neuronal Signal       Date:  2016-12-22

4.  Glycinergic Transmission in the Presence and Absence of Functional GlyT2: Lessons From the Auditory Brainstem.

Authors:  Sina E Brill; Ayse Maraslioglu; Catharina Kurz; Florian Kramer; Martin F Fuhr; Abhyudai Singh; Eckhard Friauf
Journal:  Front Synaptic Neurosci       Date:  2021-02-09

Review 5.  Synergistic Control of Transmitter Turnover at Glycinergic Synapses by GlyT1, GlyT2, and ASC-1.

Authors:  Volker Eulenburg; Swen Hülsmann
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.